title: Intravitreal bevacizumab for treatment of myopic choroidal neovascularization: the second year of a prospective study.
abstract: OBJECTIVE
  To evaluate the efficacy and safety of intravitreal bevacizumab for the treatment of myopic choroidal neovascularization (CNV).
  
  
  METHODS
  Prospective, non-randomized, interventional clinical study.
  
  
  METHODS
  Twenty eyes from 20 patients with CNV secondary to pathologic myopia participated in this study. These patients had already completed 12 months of follow-up. All patients were scheduled for 3 monthly intravitreal bevacizumab 1.25 mg injections. ETDRS best-corrected visual acuity (BCVA), foveal center thickness (FCT) on OCT and CNV size as assessed by fluorescein angiography were examined before and after treatment. Patients were followed up for 24 months.
  
  
  RESULTS
  Mean BCVA (+/- SD) at baseline was 24.8 (+/- 11.86) letters (Snellen equivalent: 20/80). At 24 months after treatment the mean BCVA (+/- SD) improved significantly (p less than 0.05) to 44 (+/- 13.99) letters (Snellen equivalent: 20/33). At 24 month follow-up, BCVA improved of 10 letters or more in 17 (85%) out of 20 treated eyes and improved of 15 letters or more in 15 (75%) eyes. No treated eyes experienced a worsening of BCVA from baseline. Mean foveal center thickness (FCT) (+/- SD) at baseline was 223 (+/- 47,43) microns. By month 24, mean FCT (+/-SD) reduced to 190 (+/- 29.01) microns (p less than 0.05). Mean area of the CNVs at baseline was 0.77 (+/- 0.78) mm2, which decreased to 0.31 +/- (0.51) mm2 and 0.30 (+/- 0.50) mm2 at 12 (p less than 0.05) and 24 months (p less than 0.05), respectively. At 24 months follow-up absence of fluoresce in leakage from the CNV was demonstrated in 18 (90%) out of 20 treated eyes. No ocular or systemic adverse effects from treatment were encountered.
  
  
  CONCLUSIONS
  Eyes with myopic CNV treated with intravitreal bevacizumab over 2 years had significant anatomic and functional improvement. Further studies will be needed to confirm the long-term efficacy and safety of this treatment.
authors.affiliation: Department of Ophthalmology, University of Rome La Sapienza, Rome, Italy. magda.gharbiya@tiscali.it
authors.forename: M
authors.initials: M
authors.lastname: Gharbiya
authors.forename: F
authors.initials: F
authors.lastname: Allievi
authors.forename: S
authors.initials: S
authors.lastname: Conflitti
authors.forename: M
authors.initials: M
authors.lastname: Esposito
authors.forename: V
authors.initials: V
authors.lastname: Scavella
authors.forename: A
authors.initials: A
authors.lastname: Moramarco
authors.forename: F
authors.initials: F
authors.lastname: Cruciani
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D058449:Intravitreal Injections; D008875:Middle Aged; D009216:Myopia / Q000150:complications; D011446:Prospective Studies; D013997:Time Factors
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab